The pharmaceutical industry is undergoing an unprecedented transformation that will undoubtedly lead to additional mergers and acquisitions, the emergence of new disruptive business models that will increase value for all stakeholders in the healthcare sector, and, most importantly, the creation of innovative medicine.
Complexity is a defining characteristic of the biopharmaceutical sector today, as seen by expanding market needs for increased specificity and safety, new therapy classes, and more complex disease processes. Maintaining this complexity calls for a greater comprehension of therapeutic behaviour.
A unique way to investigate biological and physicochemical processes right down to the atomic level is through modelling and simulation techniques as provided by BIOVIA Suite. Using the application can aid you in directing physical experimentation, speeding up the process of discovery and advancement.
BIOVIA Suite
Over 30 years of peer-reviewed research and top-tier in silico methods, including molecular mechanics, free energy calculations, biotherapeutics developability, and more, are combined in a single environment by BIOVIA Discovery Studio.
From Target ID through Lead Optimisation, it gives researchers a full toolkit to investigate the subtleties of protein chemistry and accelerate the identification of small and big molecule therapies.
The customer’s R&D work processes may readily incorporate BIOVIA’s predictive sciences capabilities, providing a scientific decision support environment that decreases time and expense, improves quality, fosters cooperation, and accelerates innovation in the development of novel medications.
The ability to forecast important physicochemical, biophysical, and pharmacological end-points inside shared workflows provided by BIOVIA predictive sciences solutions enables R&D scientists and project teams to:
Accelerate innovations and lessen reliance on experimentation: accentuate the tiny and biological molecules that are most likely to have advantageous features
- Save money and time: In order to avoid expensive and time-consuming experiments, investigate and test hypotheses in silico
- Enhance quality: boost quality before moving on to development, identify problematic pharmacological and biological developability issues early in the discovery process
- Speed optimization: Use fewer cycles to optimise bioactivity and pharmacological profiles in discovery, speeding up projects to development while using fewer resources
- Consistency: Utilize a set of prediction tools that are the same across all teams, partners, and locations
- Complement R&D initiatives: Reduce the amount of time lost on repetitive copies and pastes between different point solutions by integrating prediction tools with standard R&D operations.
- Record the most innovative scientific practices: Best research practices should be recognised and improved within a collaborative, open-platform architecture
Predictive Science Solutions
Molecular biologists, computational structural biologists, medicinal and computational chemists, and others can streamline their processes and democratise their predictive science efforts with the integrated solutions from the BIOVIA Suite.
These technologies offer the collaborative, open-platform architecture that scientists require to more effectively exploit their current knowledge, self-assuredly make data-driven judgements and leverage virtual predictive sciences for innovative medicine creation.
With a wide range of verified modelling and simulation tools for both small molecule and macromolecule-based drug design, BIOVIA Discovery Studio can accelerate life sciences research.
Excipient modelling and simulation tools are available in BIOVIA Materials Studio to assist in the development of medicinal delivery methods.
Using the BIOVIA QSAR Workbench, predictive Quantitative Structure-Activity Relationship models may be developed, validated, and deployed automatically to speed up lead optimisation.
Rapidly develop, test, and publish scientific services that automate data analysis and let researchers quickly explore, visualise, and present findings with BIOVIA Pipeline Pilot.
BIOVIA Component Collections allows you to build, deploy, and analyse complex scientific data types utilizing the discipline-specific features of BIOVIA Pipeline Pilot to speed up decision-making and advance scientific processes.
Taking Predictive Sciences to the Next Level with BIOVIA Discovery Studio
Numerous protein engineering tools, such as multiple-site mutation analysis and disulfide bridge prediction, are available through BIOVIA Discovery Studio. Molecular biologists and experts in protein/antibody design can create unique biologics that are stable and optimized using technologies like Aggregation Propensity calculations and Developability Index calculations, among others.
Computational professionals can use cutting-edge methodology to explore the biophysical properties of solvated macromolecules on the nanosecond scale thanks to market-leading force field-based methodologies.
Structure-based drug design relies heavily on methods for accurately analysing, visualising, and interpreting receptor-ligand interactions.
Using enhanced ligand-enumeration and scaffold-hopping workflows, special interaction visualisation and analysis capabilities in BIOVIA Discovery Studio allow computational experts and medicinal chemists to create and optimise small molecule medications. These new innovations enhance the tiny molecule design options already available.
Project teams’ needs for both science and workflow are met by BIOVIA Discovery Studio. Organisations may quickly apply best practice modelling techniques throughout the entire company, interact with third-party apps, and automate repetitive operations.
Get in touch
The BIOVIA Suite is the most comprehensive and collaborative predictive sciences solution for life science R&D scientists, computational experts, and project teams.
Get in touch today to find out how you can leverage virtual predictive sciences for innovative medicine Creation with the BIOVIA Suite.